🇺🇸 FDA
Pipeline program

68Ga-DOTA-NT-20.3

68Ga-DOTA-NT-20.3

Unknown other completed

Quick answer

68Ga-DOTA-NT-20.3 for Pancreatic Ductal Adenocarcinoma is a Unknown program (other) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Pancreatic Ductal Adenocarcinoma
Phase
Unknown
Modality
other
Status
completed

Clinical trials